Health

February 06, 2024

Public Comment

Department of CommerceExecutive BranchHealthPharma

Civil Society Comment on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Unfortunately, despite numerous petitions presented over the 40-plus year history of the Bayh-Dole Act, not once has a federal agency exercised its right to march-in and license competition to remedy price gouging (which constitutes a failure of the owner of a subject invention to make that invention available to the public on reasonable terms), or otherwise.

September 27, 2023 | Revolving Door Project Newsletter

KJ Boyle

Newsletter ClimateCorporate CrackdownGovernment CapacityHealth

New Watchdog Reports Highlight Insufficient EPA Enforcement Ahead Of Shutdown

Corporate greed and emaciated federal regulatory capacity means people are needlessly suffering physically, and sometimes even dying. That’s the upshot of two recent reports from the EPA’s Office of the Inspector General (OIG). These reports illustrate the concerning state of environmental regulation and enforcement in regards to water quality and refinery emissions. 

September 18, 2023

Hannah Story Brown Dorothy Slater

Press Release ClimateExecutive BranchHealth

RELEASE: White House Should Deepen Its New Recognition of the Environmental Salience of Its Cancer Moonshot Initiative

The White House announced late last week that the Environmental Protection Agency is launching epa.gov/cancer as part of the Biden administration’s Cancer Moonshot efforts, and will share new information about the EPA’s role in leveraging its existing authorities to “accelerate the rate of progress to prevent cancer, including phase-outs of carcinogens, regulatory actions to protect children, workers and overburdened communities, and enforcement actions to ensure pollution is curbed.” 

September 01, 2023

Ananya Kalahasti Will Royce

Press Release Ethics in GovernmentHealthJudiciaryPharma

RELEASE: Judge Invested in Big Pharma Shouldn't Try Case on Big Pharma Profiteering

The Revolving Door Project’s Ananya Kalahasti and Will Royce released the following statement regarding the US Chamber of Commerce’s lawsuit regarding the Inflation Reduction Act’s Medicare prescription drug negotiation program, and a financial conflict of interest regarding the judge in the Southern District of Ohio.

February 08, 2023 | Revolving Door Project Newsletter

Hannah Story Brown Ananya Kalahasti

Newsletter

Corporate CrackdownEthics in GovernmentHealthRevolving Door

Will the White House Let Covid Vaccine Prices Skyrocket?

Since the early days of the pandemic, the federal government has been pre-purchasing Covid vaccines at an average cost of around $20 per dose (around $29 per dose for the bivalent boosters) to ensure public access to vaccination at no cost. However, with Congress no longer willing to fund Covid treatment, the Biden administration has indicated that it intends to end the Covid public health emergency in May, and more or less hand over control of Covid prevention to the healthcare industry.

February 01, 2023 | Talking Points Memo

Dorothy Slater Hannah Story Brown

Op-Ed ClimateHealth

Biden Should Wed His Cancer Moonshot To The Energy Transition

But succeeding at his Cancer Moonshot’s goals will require more than funding research into cancer treatments. As the first day of February marks the beginning of National Cancer Prevention Month, it’s worth acknowledging that cancer prevention requires different approaches than treatment, and must include a reckoning with the carcinogens that pervade our environment. If Biden really wants to fight cancer in America, he’s going to have to challenge the fossil fuel and petrochemical industries. Among other things, this means confronting an Achilles heel of the Democratic Party: domestic fracking.

January 25, 2023 | Revolving Door Project Newsletter

Hannah Story Brown Emma Marsano

Newsletter

Corporate CrackdownEthics in GovernmentExecutive BranchHealthRevolving Door

Biden’s Choice of Chief of Staff Threatens Populist Potential

Last Friday marked the exact midway point of Biden’s presidential term. With this newly divided Congress, there are scant possibilities for legislation in the next two years. By and large, this next stage of Biden’s presidency should be all about the executive branch: implementing recent laws, enforcing existing laws, and enacting much-needed regulation. (Biden should have been overseeing these things all along, of course—that’s what the Presidency is for!)